Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024British Journal of CancerOpen Access

Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMarie-Paule SablinPGPierre GestraudSJSarah Flora Jonas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sablin et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc57b6db6435875720f9https://doi.org/10.1038/s41416-024-02804-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis2025
  2. 2<i>CCNE1</i> amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.2024 · 2 citations
  3. 3Genomic alterations associated with resistance and circulating tumor <scp>DNA</scp> dynamics for early detection of progression on <scp>CDK4</scp>/6 inhibitor in advanced breast cancer2024 · 8 citations
  4. 4Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer2025 · 1 citations
  5. 5Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.2024